Dual AAV gene therapy achieves recovery of hearing and auditory processing in a DFNB16 mouse model
Dual AAV-mediated gene delivery restored peripheral hearing in a DFNB16 preclinical mouse model. The same treatment also restored central auditory processing. AAV-mediated gene therapy represents a promising curative strategy for DFNB16. These results reinforce the translational potential for treating human genetic deafness.
Authors
- Amel Saoudi (ORCID: https://orcid.org/0000-0002-5495-0891)
- Brice Bathellier (ORCID: https://orcid.org/0000-0001-9211-1960)
- M. Lecomte (ORCID: https://orcid.org/0000-0001-5097-6798)
- Najate Benamer (ORCID: https://orcid.org/0000-0003-1646-1509)
- Maxence Cornille
- Sophie Bagur (ORCID: https://orcid.org/0000-0002-4375-1838)
- Sara Jamali (ORCID: https://orcid.org/0000-0003-4933-3167)
- Vincent Michel (ORCID: https://orcid.org/0000-0001-8789-8711)
- H. Le Ribeuz
- Chloé Felgerolle (ORCID: https://orcid.org/0000-0001-8824-375X)
- Marie Giorgi (ORCID: https://orcid.org/0000-0002-5505-7165)
- Sepideh Iranfar
- Saaid Safieddine
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut Pasteur (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Physiopathologie et Epidémiologie des Maladies Respiratoires (FR)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/ctm2.70571
- Primary Topic
- Hearing, Cochlea, Tinnitus, Genetics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fondation Pour l'Audition
- Agence Nationale de la Recherche
- Fondation pour la Recherche Médicale